CYTOKINETICS INC (CYTK) Stock Price, Quote, News and Overview
NASDAQ:CYTK - Nasdaq - US23282W6057 - Common Stock - Currency: USD
CYTK Quote, Performance and Key Statistics
43.43
+0.16 (+0.37%)
The current stock price of CYTK is 43.43 USD. In the past month the price decreased by -5.93%. In the past year, price decreased by -33.95%.
CYTK Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.17 | 378.30B | ||
| AMGN | AMGEN INC | 16.39 | 174.51B | ||
| GILD | GILEAD SCIENCES INC | 25.47 | 146.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1683.76 | 125.39B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.5 | 77.34B | ||
| ARGX | ARGENX SE - ADR | 231.21 | 36.10B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.66B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.47B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
| BIIB | BIOGEN INC | 9.13 | 22.01B | ||
| NTRA | NATERA INC | N/A | 19.02B | ||
| GMAB | GENMAB A/S -SP ADR | 24.89 | 15.34B |
Related stock screener links
About CYTK
Company Profile
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The company is headquartered in South San Francisco, California and currently employs 423 full-time employees. The company went IPO on 2004-04-29. The firm specializes in muscle biology and the mechanics of muscle performance. The company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Its cardiac muscle contractility program is focused on the cardiac sarcomere. Its clinical-stage drug candidates are: aficamten, which is a next-in-class cardiac myosin inhibitor; omecamtiv mecarbil, which is a cardiac myosin activator; CK-586, which is an additional cardiac myosin inhibitor, and CK-136, which is a cardiac troponin activator. CK-586 is designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction.
Company Info
CYTOKINETICS INC
350 Oyster Point Boulevard
South San Francisco CALIFORNIA 94080 US
CEO: Robert I. Blum
Employees: 423
Company Website: https://cytokinetics.com/
Investor Relations: https://ir.cytokinetics.com
Phone: 16506243000
CYTOKINETICS INC / CYTK FAQ
What is the stock price of CYTOKINETICS INC today?
The current stock price of CYTK is 43.43 USD. The price increased by 0.37% in the last trading session.
What is the ticker symbol for CYTOKINETICS INC stock?
The exchange symbol of CYTOKINETICS INC is CYTK and it is listed on the Nasdaq exchange.
On which exchange is CYTK stock listed?
CYTK stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CYTOKINETICS INC stock?
27 analysts have analysed CYTK and the average price target is 81.71 USD. This implies a price increase of 88.14% is expected in the next year compared to the current price of 43.43. Check the CYTOKINETICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CYTOKINETICS INC worth?
CYTOKINETICS INC (CYTK) has a market capitalization of 5.14B USD. This makes CYTK a Mid Cap stock.
How many employees does CYTOKINETICS INC have?
CYTOKINETICS INC (CYTK) currently has 423 employees.
What are the support and resistance levels for CYTOKINETICS INC (CYTK) stock?
CYTOKINETICS INC (CYTK) has a support level at 42.75 and a resistance level at 43.44. Check the full technical report for a detailed analysis of CYTK support and resistance levels.
Is CYTOKINETICS INC (CYTK) expected to grow?
The Revenue of CYTOKINETICS INC (CYTK) is expected to grow by 1451.37% in the next year. Check the estimates tab for more information on the CYTK EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CYTOKINETICS INC (CYTK) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CYTK, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CYTK, evaluating the profitability, health, valuation and growth aspects
- CYTOKINETICS INC (CYTK) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CYTOKINETICS INC (CYTK) Sales and EPS estimates to see what analysts future expectations are.
- CYTOKINETICS INC (CYTK) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CYTOKINETICS INC (CYTK) Insider and Institutional Ownership to learn about the owners and their transactions.
- CYTOKINETICS INC (CYTK) Stock Chart to make your own analysis
- CYTOKINETICS INC (CYTK) Latest news and press-releases to stay up to date.
Does CYTOKINETICS INC (CYTK) stock pay dividends?
CYTK does not pay a dividend.
When does CYTOKINETICS INC (CYTK) report earnings?
CYTOKINETICS INC (CYTK) will report earnings on 2025-05-06, after the market close.
What is the Price/Earnings (PE) ratio of CYTOKINETICS INC (CYTK)?
CYTOKINETICS INC (CYTK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.26).
What is the Short Interest ratio of CYTOKINETICS INC (CYTK) stock?
The outstanding short interest for CYTOKINETICS INC (CYTK) is 13.03% of its float. Check the ownership tab for more information on the CYTK short interest.
CYTK Technical Analysis
CYTK Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CYTK. Both the profitability and financial health of CYTK have multiple concerns.
CYTK Financial Highlights
Over the last trailing twelve months CYTK reported a non-GAAP Earnings per Share(EPS) of -5.26. The EPS increased by 3.49% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -42.06% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CYTK Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to CYTK. The Buy consensus is the average rating of analysts ratings from 27 analysts.
For the next year, analysts expect an EPS growth of -3.25% and a revenue growth 1451.37% for CYTK